

A limited number of genes can generate a tremendous level of complexity at the protein level due to processes such as alternative splicing and post-translational modification (PTM). PTMs are essential for many cellular functions such as protein activity, subcellular localization, degradation, and protein-protein interactions. Proteomic methods that profile PTMs provide insight into both normal and disease biology that is not feasible at the genetic level.

There are many types of PTMs including:

- » Phosphorylation
- » Methylation
- » Acetylation
- » Succinylation
- » Ubiquitination
- » Proteolytic cleavage

PTMScan®: Antibody enrichment of modified peptides for mass spectrometry-based proteomics

Cell Signaling Technology (CST™) has established PTMScan® technology, a proprietary proteomic method that employs validated PTM- and motif-specific antibodies developed by CST to enrich PTM-containing peptides prior to liquid chromatography tandem mass spectrometry (LC-MS/MS). PTMScan technology allows identification and quantification of hundreds to thousands of even low abundance PTM sites, which can then be narrowed down to the most relevant actionable targets. PTMScan technology uses a more focused approach to PTM-peptide enrichment than other strategies such as immobilized metal affinity chromatography (IMAC).

PTMScan can be used to:

- Determine novel PTM sites that are phosphorylated, ubiquitinated, acetylated, etc.
- Identify and validate drug targets
- Discover biomarkers
- Elucidate off-target drug effects
- Explore the mechanism of action of drugs/chemical modulators

Contents

- 3 Discovery vs. Direct
- 4 PTMScan® Kits vs. Services
- 5 PTMScan® Discovery and Direct Services
- 6 Complementary Services
- 7 PTMScan® Discovery Products and Services
- 12 PTMScan® Direct Services
- 13 From Bench to Bedside
- 14 Support for Drug Discovery

GENOME

Thousands of genes



TRANSCRIPTOME

Hundreds of thousands of transcripts

NCREASING COMPLEXITY



PROTEOME

Millions of proteoforms



IP with PTM/Motif Abs

Mass Spectrometry

Data Analysis



Candidates for further analysis


Key to Success: PTMScan® Antibodies

The antibodies used to enrich PTM-containing peptides are key to the success of PTMScan technology. They are:

- Designed and produced in-house
- Rigorously tested for specificity, sensitivity, and lot-to-lot consistency
- · Specially formulated for immunoaffinity enrichment

The table below outlines the three types of antibodies for PTMScan technology.

Antibody type	Recognizes	Example	
Standard site-specific PTM antibody	Modified amino acid in the context of a specific sequence of amino acids surrounding it.	A CST [™] antibody to Akt1 phosphory-lated at serine 473 only recognizes that particular phosphoserine and the surrounding amino acids.	P FPQFSYSAS
Motif antibody	Modified amino acid within a certain motif.	The Akt substrate motif antibody will recognize the sequence RXRXXS* in any protein only when the serine residue is phosphorylated (where X can be any amino acid).	XRXRXXSXX
PTM-specific antibody (PTM-antibody)	Any peptide with the PTM of interest.	A CST acetyl-lysine antibody will recognize all acetylation sites independent of flanking amino acid sequences.	Ac



Discovery vs. Direct


Which option is right for your research?

	PTMScan® Discovery (PTM/motif-based enrichment) PTM/motif Abs	PTMScan® Direct (mass spectrometry-based antibody array) Site-specific Abs to defined targets
Is a specific pathway targeted?	×	✓
Is antibody enrichment performed?	~	✓
Is LC-MS/MS performed?	✓	✓
What type of antibodies are used?	PTM or motif antibodies to undefined targets.	Standard site-specific antibodies to defined targets within the known pathway(s) of interest.
What is the bead format?	Antibodies against one PTM or motif on each bead.	Antibodies against many targets on each bead (a bead-based multiplex assay).
Which species can you use?	Can be used on samples from many different species including, but not limited to, human, mouse, rat, drosophila, and arabidopsis.	Validated for human and mouse. (Contact us for other species.)
Case Study	"Deep, quantitative coverage of the acetylome using novel anti-acetyl-lysine antibodies and an optimized proteomic workflow." Svinkina, T., et al (2015) <i>Mol. Cell. Proteomics</i> 14(9):2429–40.	"PTMScan Direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS." Stokes, M., et al (2012) <i>Mol Cell Proteomics</i> . 11(5):187–201.
Summary	Use PTMScan Discovery to find new information with quantitative analysis of PTMs.	Use PTMScan Direct to quantitatively assay the activity of components of known signaling pathways across cell lines or treatments.

PTMScan® Kits vs. Services

PTMScan® Kits

With PTMScan® Antibody Kits you can perform your own enrichment and LC-MS/MS analysis. They provide the antibody reagents for 10* peptide enrichment experiments and the detailed protocols needed to discover new sites of post-translational modification.§






PTMScan® Services


CST scientists work with you from project planning to delivery of a comprehensive data package that includes:

- Qualitative/quantitative tables
- Informatics tables
- Microsoft® PowerPoint® summary
- Microsoft® Word® guide to prioritizing follow-up candidates



PTMScan® Discovery and Direct Services

Workflow



PTMScan® Service Data

The data set generated by a PTMScan® service experiment includes quantification of PTM changes, the identity of each protein, and specific location of each modification site.

Normalized Fold Change						
SU11274 vs. DMSO Control	Staurosporine vs. DMSO Control	Protein Name	Site	-7/+ 7 Sequence	Peptide	Upstream Kinase
-5.0	-4.6	EphA2	897	RVSIRLPsTSGSEGV	LPS*T*SGSEGVPFR	Akt1
-13.6	-2.1	F0X01A	319	TFRPRTSSNASTISG	TSS*NASTISGR	Akt1
-158.0	-7.2	F0X04	32	QSRPRSCtWPLPRPE	SCT*WPLPRPEIANQPSEPPEVEPDLGEK	Akt1
-3.4	1.8	QIK	358	DGRQRRPSTIAEQTV	RPS*TIAEQTVAK	Akt1, Akt2
-13.3	-29.4	S6	235, 236, 240	IAKRRRLsSLRASTS	RLS*S*LRAS*TSK	Akt1, Akt2, P70S6Kβ, PKACα, PKCα, PKCδ
-7.0	-24.5	S6	236, 240	AKRRRLSSLRASTSK	RLSS*LRAS*TSK	Akt1, Akt2, P70S6Kβ, PKACα, PKCα, PKCδ
2.6	1.1	BRAF	365	GQRDRSSsapnvhin	SSS*APNVHINTIEPVNIDDLIR	Akt1, Akt3
-7.0	-9.4	GSK3β	9	SGRPRTTsFAESCKP	TTS*FAESCKPVQQPSAFGSMK	Akt1, AurA, CAMK2β, GSK3β, KHS1, PKACα, PKCα
-5.3	-N.D.	GSK3β	9, 21	SGRPRTTsFAESCKP	TTS*FAESCKPVQQPS*AFGSMK	Akt1, AurA, CAMK2B, GSK3β, KHS1, PKACα, PKCα
-21.3	-3.0	PEA-15	116	KDIIRQPSEEEIIKL	DIIRQPS*EEEIIK	Akt1, CAMK2a, CK2a1
-2.1	-2.9	GSK3a	21	SGRARTSSFAEPGGG	TSS*FAEPGGGGGGGGGGGGGSASGPGGTGGGK	Akt1, CAMK2β, PKACA, PKCα, PKCβ
-10.3	-1.8	RANBP3	126	VKRERTSSLTQFPPS	TSS*LTQFPPSQSEER	Akt1, ERK1, RSK2, p90RSK
2.7	2.5	elF4B	422	RERSRTGSESSQTGT	TGS*ESSQTGTSTTSSR	Akt1, p70S6K, p90RSK
4.8	2.5	elF4B	422, 425	RERSRTGSESSQTGT	TGS*ESS*QTGTSTTSSR	Akt1, p70S6K, p90RSK

Table view presentation of data from PTMScan® analysis of MKN-45 cells treated with SU11274 or staurosporine. Shown are representative data for the basophilic Akt substrate motifs RXRXX(s/t) and RXX(s/t). Relative abundance changes of 2.5-fold or greater (treated versus control) for phosphorylated peptides are indicated by green (increase) or red (reduction) highlighting.



Nous contacter

Service client - commande : commande@ozyme.fr

Service technique:

Réactifs: 01 34 60 60 24 - tech@ozyme.fr

Instrumentation: 01 30 85 92 88 - instrum@ozyme.fr